Nymox Pharmaceutical Corp SEC filings NYMXF
Nymox Pharmaceutical Corp has 408 filings in SEC EDGAR's recent list, going back to Aug 8, 1996. Its latest annual report, Form 20-F, was filed on Sep 14, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Aug 31, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| NT 20-F | Form 20-f | May 1, 2025 | Dec 31, 2024 |
| 25-NSE | Delisting notice | Sep 8, 2023 | — |
| NT 20-F | Filing | Mar 31, 2023 | Dec 31, 2022 |
| EFFECT | Filing | Apr 12, 2022 | — |
| CORRESP | Letter to the SEC | Apr 6, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 4, 2022 | — |
| EFFECT | Filing | Jan 28, 2022 | — |
| CORRESP | Letter to the SEC | Jan 25, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 22, 2021 | — |
| EFFECT | Filing | May 20, 2021 | — |
| CORRESP | Letter to the SEC | May 17, 2021 | — |
| UPLOAD | Letter from the SEC | May 14, 2021 | — |
| EFFECT | Filing | May 12, 2020 | — |
| CORRESP | Letter to the SEC | May 7, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 10, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2016 | — |
| CORRESP | Letter to the SEC | Nov 15, 2016 | — |
| UPLOAD | Letter from the SEC | Nov 1, 2016 | — |
| UPLOAD | Letter from the SEC | Sep 21, 2016 | — |
| EFFECT | Filing | Aug 4, 2015 | — |
| CORRESP | Letter to the SEC | Aug 4, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 24, 2015 | — |
| UPLOAD | Letter from the SEC | Aug 15, 2013 | — |
| CORRESP | Letter to the SEC | Aug 13, 2013 | — |
| UPLOAD | Letter from the SEC | Aug 6, 2013 | — |
| CORRESP | Letter to the SEC | Jul 31, 2013 | — |
| UPLOAD | Letter from the SEC | Jul 24, 2013 | — |
| CORRESP | Letter to the SEC | Jul 15, 2013 | — |
| UPLOAD | Letter from the SEC | Jul 5, 2013 | — |
| CT ORDER | Filing | Aug 26, 2011 | — |
| UPLOAD | Letter from the SEC | Oct 27, 2005 | — |
| CORRESP | Letter to the SEC | Oct 3, 2005 | — |
| UPLOAD | Letter from the SEC | Aug 25, 2005 | — |
| CORRESP | Letter to the SEC | Aug 5, 2005 | — |
| 20FR12G/A | Form 20-f amendment #6 | Apr 9, 1997 | — |
| 20FR12G/A | Form 20-f amendment #5 | Apr 3, 1997 | — |
| 20FR12G/A | Form 20-f | Mar 20, 1997 | — |
| 20FR12G/A | Nymox pharmaceutical corporation pre-effective amendment no.3 | Feb 21, 1997 | — |
| 20FR12G/A | Amdt. no. 2 to 20-f | Jan 31, 1997 | — |
| 20FR12G/A | Amdt. no. 1 to 20-f | Dec 9, 1996 | — |
| 20FR12G | Form 20-f for nymox pharmaceutical corp. | Aug 8, 1996 | — |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- NYMXF (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Quebec Canada, Quebec, Canada
- SEC filer status
- Accelerated filer
- SEC CIK
- 1018735
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.